Consolidated revenue KRW 6.66B (down 11.6% YoY from KRW 7.53B), operating loss KRW 5.25B (narrowed from KRW 6.68B), net loss KRW 6.52B (narrowed from KRW 7.47B)
Total liabilities KRW 24.6B, down 58.4% from year-end; borrowings KRW 14.9B, down 69% (fully repaid ofmom borrowings KRW 28.0B and major shareholder KRW 5.0B)
Cash and cash equivalents KRW 62.2B (down 39.8% from KRW 103.4B), net debt ratio -109% (net cash)
Completed rights offering of 49,210,000 shares in Dec 2025 (capital expansion)
New drug: OVM-200 cancer vaccine preparing for phase 1b/2a; universal COVID-19 vaccine planning phase 2; mRNA cancer vaccine tech transfer in Jul 2025
Healthcare: China supply contracts delayed (regulatory issues), revenue decline; Medical diagnostics: genomic diagnostics revenue KRW 0.95B (up 47.7% YoY)
R&D expenses KRW 2.22B (33.4% of revenue), 83 R&D projects
Largest shareholder Youn Jung Yoon holds 57.78%
Litigation with former CEO of Evixgen pending (deemed immaterial)